OmniAb, Inc. - Common Stock (OABI)
Competitors to OmniAb, Inc. - Common Stock (OABI)
AbCellera Biologics Inc. ABCL -4.61%
AbCellera Biologics focuses on using its advanced antibody discovery platform to streamline the process of developing therapeutic antibodies. It competes with OmniAb by leveraging its proprietary technology to accelerate drug discovery and improve development timelines, attracting partnerships with various pharmaceutical companies seeking rapid solutions. AbCellera's strong collaborations and partnerships with established biopharmaceutical firms provide it a notable advantage in terms of validation and funding.
Coherus BioSciences, Inc. CHRS -6.57%
Coherus BioSciences specializes in developing biosimilars and biologics, competing with OmniAb by offering alternative therapies that can introduce cost-effective solutions in healthcare. While Coherus focuses on major therapeutic areas, OmniAb differentiates itself through its proprietary platform for antibody generation, suggesting a competition between established biosimilars and novel antibody therapies, with OmniAb gaining leverage in innovation.
Genmab A/S GMAB -4.35%
Genmab engages in the creation and development of differentiated antibody therapeutics to treat cancer. Competing with OmniAb, Genmab has a more established presence and financial backing, allowing it to undertake larger clinical trials and commercialize products at a faster pace. Their competitive advantage lies in their extensive experience and a strong portfolio of therapeutic candidates that have advanced to various stages of clinical evaluation.
Kymab Limited
Kymab develops monoclonal antibodies for therapeutic uses, targeting several diseases, which positions them similarly to OmniAb. They focus on improving the humanization of antibodies and harnessing advanced platform technologies. However, Kymab’s focus on specific targets and partnerships in the specialized monoclonal space gives it certain competitive advantages in niche areas, while OmniAb has a more general approach.
Sorrento Therapeutics, Inc.
Sorrento Therapeutics has a diverse portfolio of therapeutics and technologies, including its own proprietary antibody generation platform. The competition with OmniAb arises from Sorrento’s robust pipeline and its focus on innovative cancer therapies, framing it as a significant player in the antibody market. Sorrento's broader development scope may offer them a competitive advantage, especially in terms of resource leverage and clinical results.